Results 311 to 320 of about 122,145 (339)

Association between glucagon‐like peptide‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database

Diabetes, obesity and metabolism
To evaluate the potential association between suicidality and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), as well as other medications used for obesity and diabetes, using comprehensive global data.
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, Hanseul Cho, Jaeyu Park, Hyesu Jo, Yejun Son, Soeun Kim, Jiseung Kang, Lee Smith, M. Rahmati, G. Fond, Laurent Boyer, D. Pizzol, Hayeon Lee, Sang Youl Rhee, Jiyoung Hwang, Hyunji Sang, D. Yon   +18 more
semanticscholar   +1 more source

Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation

JAMA Cardiology
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Sadiya S, Khan, William A, Grobman, Dhruv S, Kazi   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonist Treatment for Pediatric Obesity

2015
Obesity is a complex and retractable disease for which effective and durable treatments are elusive. Successful treatment of severe obesity with lifestyle modification therapy alone is highly unlikely, particularly for adolescents. Pharmacotherapy, if appropriately prescribed, can be an effective tool to use in conjunction with lifestyle modification ...
openaire   +2 more sources

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

The Lancet Gastroenterology and Hepatology, 2022
Alessandro Mantovani, Christopher D Byrne, Giovanni Targher   +2 more
exaly  

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Endocrine Reviews, 2023
Daniel J Drucker
exaly  

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor

British Journal of Pharmacology, 2022
Thomas Munzel, Andreas Daiber, Sebastian Steven   +2 more
exaly  

Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA)

2022
Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller, Katherine R. Tuttle   +3 more
openaire   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?

JAMA Internal Medicine, 2022
Shanzay, Haider, Kasia J, Lipska
openaire   +2 more sources

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

Journal of the American Heart Association, 2020
Ignatios Ikonomidis, George Pavlidis, John Thymis   +2 more
exaly  

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis

Journal of Pediatrics, 2021
Paul M Ryan, Sean Seltzer, Nathaniel E Hayward   +2 more
exaly